Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAdit SinghalDMDavid Mueller

Discussion

Loading...

Member takes

Overview

Retrospective review finds modest efficacy of low-dose decitabine and venetoclax in elderly patients with AML and MDS, suggesting acceptable tolerability and improved quality of life.

Key Points

  • Overall response rate was 28% in elderly patients with AML and MDS.
  • Study revealed that adverse events were minimal with 47% completing induction therapy.
  • The regimen showed improvements in quality of life for those receiving low-dose treatment.
  • Findings highlight a potential alternative treatment strategy for frail and elderly patients.

Cite This Study

Singhal et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da09https://doi.org/10.1182/blood-2025-5186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  4. 4Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence2025
  5. 5Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025